Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated March 30, 2026, reports a significant regulatory milestone for the company's respiratory portfolio. The filing announces the approval of Exdensur (depemokimab) by China's National Medical Products Administration (NMPA) for the add-on maintenance treatment of severe asthma with an eosinophilic phenotype in adults and pediatric patients aged 12 and older.
Key Financial Metrics
The filing text does not provide specific financial data, including revenue, profit, cash flow, margins, debt, or liquidity metrics. This document is a current report focused on a regulatory approval and clinical trial data rather than a financial statement.
Material Changes and Clinical Data
The primary material change is the expansion of Exdensur's commercial footprint into China, a market with an estimated 2 million people affected by severe asthma. The approval is based on the SWIFT-1 and SWIFT-2 Phase III trials, which demonstrated:
- Exacerbation Reduction: A 58% reduction in annualized asthma exacerbations in SWIFT-1 and a 48% reduction in SWIFT-2 compared to placebo.
- Hospitalization Reduction: A 72% reduction in the annualized rate of clinically significant exacerbations requiring hospitalization or emergency department visits in a pooled analysis.
- Dosing Advantage: Exdensur is the first ultra-long-acting biologic in China for this indication, requiring only two doses per year.
- Safety Profile: The drug was well-tolerated with side effect rates similar to placebo.
Outlook, Management Commentary, and Risks
Management Commentary: Kaivan Khavandi, SVP of Global Head, Respiratory, Immunology & Inflammation R&D, stated that the approval represents an important advance for patients and could "redefine care" by providing sustained suppression of type 2 inflammation with twice-yearly dosing. GSK aims to transform the treatment paradigm in severe asthma.
Pipeline and Outlook:
- Exdensur is already approved in the US, Japan, EU, and UK for severe asthma and/or chronic rhinosinusitis with nasal polyps (CRSwNP).
- The NMPA is currently reviewing Exdensur for the treatment of severe CRSwNP in China.
- GSK is evaluating depemokimab in Phase III trials for other conditions, including eosinophilic granulomatosis with polyangiitis (OCEAN), hyper eosinophilic syndrome (DESTINY), and COPD (ENDURA-1, ENDURA-2, VIGILANT).
Risks: The filing includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially due to risks described in GSK's Annual Report on Form 20-F for 2025.
Key Facts for Investor Verification
- Verify the commercial launch timeline and pricing strategy for Exdensur in the Chinese market.
- Monitor the status of the NMPA review for Exdensur in chronic rhinosinusitis with nasal polyps (CRSwNP).
- Track upcoming data readouts from the COPD (ENDURA/VIGILANT) and rare disease (OCEAN/DESTINY) Phase III trials.
- Assess the competitive landscape for ultra-long-acting biologics in China's severe asthma market.